XM bietet keine Dienstleistungen für Personen mit Wohnsitz in den Vereinigten Staaten von Amerika an.
B
B

Biogen


Nachrichten

About 4% of US adults age 65 and older have a dementia diagnosis, survey finds

About 4% of US adults age 65 and older have a dementia diagnosis, survey finds By Christy Santhosh June 13(Reuters) - Some 4% of U.S. adults aged 65 and older say they have been diagnosed with dementia, a rate that reached 13% for those at least 85-years old, according to a report of a national survey released on Thursday. The report issued by the U.S.
B

Biogen executive plays down looming competition for its Alzheimer's drug

UPDATE 1-Biogen executive plays down looming competition for its Alzheimer's drug Adds executive comments in paragraphs 3-4, analysts' comments in paragraphs 9-11 By Sriparna Roy June 12 (Reuters) - Biogen's BIIB.O Alzheimer's drug, Leqembi, will do well in the market whether a competitor comes or not, a company executive said at the Goldman Sachs Global Healthcare Conference on Wednesday.
B
G

Biogen executive says its Alzheimer's drug will do well in market despite competition

Biogen executive says its Alzheimer's drug will do well in market despite competition June 12 (Reuters) - Biogen's BIIB.O Alzheimer's drug, Leqembi, will do well in the market, whether a competitor will come or not, a company executive said at the Goldman Sachs Global Healthcare Conference on Wednesday. Reporting by Sriparna Roy in Bengaluru; Editi
B

Alzheimer's is a $100 bln pharma opportunity, says HSBC

BUZZ-Alzheimer's is a $100 bln pharma opportunity, says HSBC ** Brokerage HSBC says Biogen BIIB.O and partner Eisai's 4523.T Leqembi and Eli Lilly's LLY.N donanemab could start shaping a $100 bln U.S. market for Alzheimer's disease treatments ** Leqembi was given full approval by the U.S. FDA last year and donanemab won an unanimous endorsement by an advisory panel on Monday ** HSBC says overwhelming support for donanemab's approval highlights not only a positive benefit-risk profile for the new
B

Japan's Nikkei gains on chip shares boost; Fed policy in focus

Japan's Nikkei gains on chip shares boost; Fed policy in focus Updates with closing levels By Brigid Riley TOKYO, June 11 (Reuters) - Japan's Nikkei share average closed at a two-month peak on Tuesday as heavyweight chip shares tracked their Wall Street peers higher, while investors braced for the Federal Reserve's p olicy decision later this week . S entiment was up during early Tokyo trading after the S&P 500 and Nasdaq both logged record closing highs overnight .
B
U
J
U

FDA advisory panel backs Lilly Alzheimer's drug

FDA advisory panel backs Lilly Alzheimer's drug June 10(Reuters) - A panel of expert advisers to the U.S. Food and Drug Administration voted unanimously on Monday to back Eli Lilly's LLY.N experimental Alzheimer's drug, donanemab, saying its benefits outweigh risks posed by the treatment. Lilly's drug is a potential rival to Eisai 4523.T and Biogen's BIIB.O Leqembi, which won U.S.
B

Lilly Alzheimer's drug gets unanimous backing from FDA advisory panel

UPDATE 5-Lilly Alzheimer's drug gets unanimous backing from FDA advisory panel Adds final vote in first paragraph, details from panel meeting throughout, comments in paragraphs 3 and 20, share move By Bhanvi Satija and Julie Steenhuysen June 10 (Reuters) - Outside advisers to the U.S. Food and Drug Administration on Monday voted unanimously that the benefits of Eli Lilly's LLY.N experimental Alzheimer's treatment donanemab outweighed its risks, and agreed that trial data showed it was effective
B

US FDA advisers to review Eli Lilly Alzheimer's drug

US FDA advisers to review Eli Lilly Alzheimer's drug By Bhanvi Satija and Julie Steenhuysen June 10 (Reuters) - An independent advisory panel to the U.S. Food and Drug Administration will vote later on Monday on the safety and effectiveness of Eli Lilly's LLY.N experimental Alzheimer's drug donanemab. Donanemab, if approved, would compete with Eisai 4523.T and Biogen's BIIB.O Leqembi.
B

Eisai Says FDA Accepts Co's Filing Of Leqembi® Supplemental Biologics License Application For IV Maintenance Dosing

BRIEF-Eisai Says FDA Accepts Co's Filing Of Leqembi® Supplemental Biologics License Application For IV Maintenance Dosing June 9 (Reuters) - Biogen Inc BIIB.O : FDA ACCEPTS EISAI'S FILING OF LEQEMBI® (LECANEMAB-IRMB) SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION FOR IV MAINTENANCE DOSING FOR THE TREATMENT OF EARLY ALZHEIMER'S DISEASE EISAI- PDUFA AC
B

What to Watch in the Week Ahead and on Monday, June 10

What to Watch in the Week Ahead and on Monday, June 10 The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ahead, Eikon users can register at DAY/US . Thomson One users can register at RT/DAY/US. All times in ET/GMT ON MONDAY Morgan Stanley CEO Ted Pick is scheduled to speak at the bank's annual U.S.
A
B
B
C
D
T
A
B

US FDA staff raise no major concerns about Eli Lilly Alzheimer's drug

UPDATE 3-US FDA staff raise no major concerns about Eli Lilly Alzheimer's drug Adds details from FDA, Lilly documents in paragraphs 9, 11-16, 18-19, analyst comment in paragraph 17 By Bhanvi Satija and Julie Steenhuysen June 6 (Reuters) - An FDA analysis of trial data for Eli Lilly's LLY.N experimental Alzheimer's drug donanemab released on Thursday revealed no red flags, but raised questions about safety of the treatment for patients with early-stage disease.
B

US FDA panel to vote on data, risk profile of Lilly Alzheimer's drug

US FDA panel to vote on data, risk profile of Lilly Alzheimer's drug June 6 (Reuters) - A panel of outside experts to the U.S. health regulator will vote on Monday on whether data for Eli Lilly's LLY.N experimental treatment, donanemab, shows it is effective for treating patients with early Alzheimer's disease. The panel will also vote on whether benefits of the treatment outweigh its risks, according to documents published on the agency's website.
B

Novartis, Roche unit and others face Italy antitrust probe over eye drug

UPDATE 3-Novartis, Roche unit and others face Italy antitrust probe over eye drug Adds Biogen comment in last paragraph ROME, June 6 (Reuters) - Italy's antitrust regulator said on Thursday it had launched an investigation into pharmaceutical companies including Novartis NOVN.S and Roche-controlled ROG.S Genentech for having potentially restricted competition in the sale of an eye drug.
B
N
R

Novartis and others face Italy antitrust probe over eye drug

Novartis and others face Italy antitrust probe over eye drug ROME, June 6 (Reuters) - Italy's antitrust regulator said on Thursday it had launched a probe into several pharmaceutical companies, including Novartis NOVN.S , for having potentially restricted competition in the sale of a drug for eye conditions. Samsung Bioepis, Biogen, Genentech and Novartis, and some of their Italian, Dutch and UK units, allegedly coordinated their commercial strategies to delay the launch in Italy of Byooviz, a d
B
N
R

European Commission grants marketing approval to Biogen's ALS drug

UPDATE 2-European Commission grants marketing approval to Biogen's ALS drug Adds background in paragraphs 5 to 9 May 30 (Reuters) - Biogen BIIB.O said on Thursday that the European Commission has granted marketing authorization under exceptional circumstances for its amyotrophic lateral sclerosis (ALS) drug Qalsody. The approval is based on a 108-patient trial that showed Qalsody reduced levels of a neurofilament protein that scientists believe is tied with the disease's progression.
B

European Commission grants marketing approval to Biogen's ALS drug

European Commission grants marketing approval to Biogen's ALS drug May 30 (Reuters) - Biogen BIIB.O said on Thursday that the European Commission has granted marketing authorization under exceptional circumstances for its amyotrophic lateral sclerosis (ALS) drug Qalsody. Reporting by Sneha S K in Bengaluru; Editing by Alan Barona
B

Biogen Says "Leqembi®" (Lecanemab) Approved For Treatment Of Alzheimer's Disease In South Korea

BRIEF-Biogen Says "Leqembi®" (Lecanemab) Approved For Treatment Of Alzheimer's Disease In South Korea May 26 (Reuters) - Biogen Inc BIIB.O : “LEQEMBI®” (LECANEMAB) APPROVED FOR THE TREATMENT OF ALZHEIMER’S DISEASE IN SOUTH KOREA IN SOUTH KOREA, EISAI KOREA INC. WILL DISTRIBUTE THE PRODUCT AND CONDUCT INFORMATION PROVISION ACTIVITIES Source
B

Deals of the day-Mergers and acquisitions

Deals of the day-Mergers and acquisitions Adds Hargreaves Lansdown, Lagardere, SocGen, European Energy Exchange; updates Anglo American May 22 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1930 GMT on Wednesday: * * A consortium comprising CVC Advisers and the Abu Dhabi Investment Authority said it was considering a possible revised offer for Hargreaves Lansdown HRGV.L after the British investment platform's board rejected a buyout proposal it had made in A
B
D
H
L
N
S
A
G

Deals of the day-Mergers and acquisitions

Deals of the day-Mergers and acquisitions Adds: Biogen, Oaktree Capital Management Updates: Anglo American, Abu Dhabi National Oil Company May 22 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1330 GMT on Wednesday: ** Anglo American AAL.L rejected a takeover proposal from BHP Group BHP.AX that valued the company at 29.34 pounds per share.
B
A
G

Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio With Agreement To Acquire Human Immunology Biosciences

BRIEF-Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio With Agreement To Acquire Human Immunology Biosciences May 22 (Reuters) - Biogen Inc BIIB.O : BIOGEN BOLSTERS LATE-STAGE PIPELINE, EXPANDS IMMUNOLOGY PORTFOLIO WITH AGREEMENT TO ACQUIRE HUMAN IMMUNOLOGY BIOSCIENCES BIOGEN INC: BIOGEN WILL MAKE AN UPFRONT PAYMENT TO HI-BIO OF $1.15 BILLION.
B



Konditionen

Beliebte Finanzwerte

Rechtlicher Hinweis: Die Unternehmen der XM Group bieten Dienstleistungen ausschließlich zur Ausführung an sowie Zugang zu unserer Online-Handelsplattform. Durch diese können Personen die verfügbaren Inhalte auf oder über die Internetseite betrachten und/oder nutzen. Eine Änderung oder Erweiterung dieser Regelung ist nicht vorgesehen und findet nicht statt. Der Zugang wird stets geregelt durch folgende Vorschriften: (i) Allgemeine Geschäftsbedingungen; (ii) Risikowarnungen und (iii) Vollständiger rechtlicher Hinweis. Die bereitgestellten Inhalte sind somit lediglich als allgemeine Informationen zu verstehen. Bitte beachten Sie, dass die Inhalte auf unserer Online-Handelsplattform keine Aufforderung und kein Angebot zum Abschluss von Transaktionen auf den Finanzmärkten darstellen. Der Handel auf Finanzmärkten birgt ein hohes Risiko für Ihr eingesetztes Kapital.

Sämtliche Materialien, die auf unserer Online-Handelsplattform veröffentlicht sind, dienen ausschließlich dem Zweck der Weiterbildung und Information. Die Materialien beinhalten keine Beratung und Empfehlung im Hinblick auf Finanzen, Anlagesteuer oder Handel und sollten nicht als eine dahingehende Beratung und Empfehlung aufgefasst werden. Zudem enthalten die Materialien keine Aufzeichnungen unserer Handelspreise sowie kein Angebot und keine Aufforderung für jegliche Transaktionen mit Finanzinstrumenten oder unverlangte Werbemaßnahmen für Sie zum Thema Finanzen. Die Materialien sollten auch nicht dahingehend aufgefasst werden.

Alle Inhalte von Dritten und die von XM bereitgestellten Inhalte sowie die auf dieser Internetseite zur Verfügung gestellten Meinungen, Nachrichten, Forschungsergebnisse, Analysen, Kurse, sonstigen Informationen oder Links zu Seiten von Dritten werden ohne Gewähr bereitgestellt. Sie sind als allgemeine Kommentare zum Marktgeschehen zu verstehen und stellen keine Anlageberatung dar. Soweit ein Inhalt als Anlageforschung aufgefasst wird, müssen Sie beachten und akzeptieren, dass der Inhalt nicht in Übereinstimmung mit gesetzlichen Bestimmungen zur Förderung der Unabhängigkeit der Anlageforschung erstellt wurde. Somit ist der Inhalt als Werbemitteilung unter Beachtung der geltenden Gesetze und Vorschriften anzusehen. Bitte stellen Sie sicher, dass Sie unseren Hinweis auf die nicht unabhängige Anlageforschung und die Risikowarnung im Hinblick auf die vorstehenden Informationen gelesen und zur Kenntnis genommen haben, die Sie hier finden.

Risikowarnung: Es bestehen Risiken für Ihr eingesetztes Kapital. Gehebelte Produkte sind nicht für alle Anleger geeignet. Bitte beachten Sie unseren Risikohinweis.